Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Sep 17;52(3):1800458.
doi: 10.1183/13993003.00458-2018. Print 2018 Sep.

Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease

Stefan Guth  1   2 , Christoph B Wiedenroth  1   2 , Andreas Rieth  3   4 , Manuel J Richter  5 , Ekkehard Gruenig  6 , Hossein Ardeshir Ghofrani  5 , Matthias Arlt  7 , Christoph Liebetrau  3   4   8 , Diethard Prüfer  1 , Andreas Rolf  3   4   8 , Christian W Hamm  3   4   8 , Eckhard Mayer  1
Affiliations
Free article
Observational Study

Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease

Stefan Guth et al. Eur Respir J. .
Free article

Abstract

Symptomatic patients with chronic thromboembolic disease (CTED) without pulmonary hypertension often show an excessive increase in mean pulmonary arterial pressure (MPAP) during exercise.We report on the impact of pulmonary endarterectomy (PEA) on pulmonary haemodynamics in a prospective series of 32 consecutive CTED patients who underwent PEA. All patients had a comprehensive diagnostic work-up including right heart catheterisation at baseline and 12 months after PEA. Furthermore, in 12 patients exercise right heart catheterisation was performed before and after PEA.After PEA, MPAP was lower at rest (20±3 versus 17±3 mmHg; p=0.008) and during maximal exercise (39±8 versus 31±6 mmHg; p=0.016). The mean total pulmonary resistance (TPR) decreased from 3.6±0.8 Wood Units (WU) pre-operatively to 2.7±0.7 WU 1 year after PEA (p=0.004) and the mean slope of the MPAP/cardiac output (CO) relationship decreased from 3.6±1.0 to 2.3±0.8 WU (p=0.002). Peak oxygen uptake increased from 1.2±0.4 to 1.5±0.3 L·min-1 (p=0.014) and ventilatory equivalents of carbon dioxide decreased from 39±2 to 30±2 (p=0.002). There was a significant improvement in quality of life assessed by the Cambridge Pulmonary Hypertension Outcome Review questionnaire.In CTED patients, PEA resulted in haemodynamic and clinical improvements. The means of TPR and MPAP/CO slopes decreased to <3.0 WU.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Guth reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees from Actelion Pharmaceuticals, Bayer, Pfizer and GSK, outside the submitted work. Conflict of interest: C.B. Wiedenroth reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees from Actelion, Bayer AG, BTG, MSD and Pfizer, outside the submitted work. Conflict of interest: A. Rieth reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees from Actelion Pharmaceuticals, Novartis, Servier and St Jude Medical, and grants from Pfizer, outside the submitted work. Conflict of interest: M.J. Richter reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees and nonfinancial support from Actelion Pharmaceuticals, personal fees from Bayer, Mundipharma, OMT and Roche, outside the submitted work. Conflict of interest: H.A. Ghofrani reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; grants and personal fees from Actelion Pharmaceuticals, Bayer, Pfizer and Novartis, personal fees from Bellerophon Pulse Technologies, Medscape, OMT, UCB Celltech, WebMD Global, Gilead Sciences, GSK and Merck, outside the submitted work. Conflict of interest: C. Liebetrau reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees from Abbott, Bayer, Pfizer, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Daiichi Sankyo and Elixir Medical, outside the submitted work. Conflict of interest: A. Rolf reports personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer-Bristol-Myers Squibb, outside the submitted work. Conflict of interest: C.W. Hamm reports nonfinancial support from the German Center for Lung Research, during the conduct of the study. Conflict of interest: E. Mayer reports nonfinancial support from the German Center for Lung Research, during the conduct of the study; personal fees from Actelion Pharmaceuticals, Bayer, Pfizer, GSK and MSD, outside the submitted work. Conflict of interest: E. Gruenig has received fees for lectures and/or consultations from Actelion Pharmaceuticals, Bayer/MSD, GSK, United Therapeutics and Pfizer.

Comment in

Publication types

MeSH terms

LinkOut - more resources